ATE235244T1 - Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten - Google Patents
Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheitenInfo
- Publication number
- ATE235244T1 ATE235244T1 AT99948982T AT99948982T ATE235244T1 AT E235244 T1 ATE235244 T1 AT E235244T1 AT 99948982 T AT99948982 T AT 99948982T AT 99948982 T AT99948982 T AT 99948982T AT E235244 T1 ATE235244 T1 AT E235244T1
- Authority
- AT
- Austria
- Prior art keywords
- neurological
- prevention
- composition
- treatment
- pathopsychological
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 150000008106 phosphatidylserines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10623098P | 1998-10-30 | 1998-10-30 | |
| PCT/EP1999/007688 WO2000025793A1 (en) | 1998-10-30 | 1999-10-13 | Compositions for the treatment and prevention of neurological and pathopsychological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE235244T1 true ATE235244T1 (de) | 2003-04-15 |
Family
ID=22310256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99948982T ATE235244T1 (de) | 1998-10-30 | 1999-10-13 | Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6514973B1 (de) |
| EP (1) | EP1124559B1 (de) |
| JP (1) | JP2002528507A (de) |
| AT (1) | ATE235244T1 (de) |
| AU (1) | AU6202299A (de) |
| CA (1) | CA2348390C (de) |
| DE (1) | DE69906345T2 (de) |
| ES (1) | ES2194513T3 (de) |
| WO (1) | WO2000025793A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7591995B2 (en) | 1999-10-15 | 2009-09-22 | Mayo Foundation For Medical Education And Research | Cobalamin conjugates useful as imaging and therapeutic agents |
| US20020176881A1 (en) * | 2001-01-26 | 2002-11-28 | George Verlaan | Rehydration composition |
| ES2227479T3 (es) * | 2001-03-26 | 2005-04-01 | Giventis Gmbh | Alimento destinado a aumentar la capacidad cognitiva. |
| EP1302196A1 (de) * | 2001-10-16 | 2003-04-16 | Habinger, René, Ing. Mag. | Intelligenzfördernde Zahncreme |
| EP3184107A1 (de) * | 2002-06-19 | 2017-06-28 | N.V. Nutricia | Verfahren und zubereitung zur behandlung von metabolischem stress |
| US7033612B2 (en) * | 2003-01-03 | 2006-04-25 | Kang David S | Composition and method for treating age-related disorders |
| IL154318A (en) | 2003-02-06 | 2010-05-31 | Sarah Herzog Memorial Hospital | Pharmaceutical compositions for the treatment of movement disorders |
| IL158139A0 (en) * | 2003-09-25 | 2004-09-27 | Enzymotec Ltd | Stabilized formulations of phosphatidyl serine |
| US7935365B2 (en) * | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
| US20050130937A1 (en) * | 2003-10-22 | 2005-06-16 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
| US8052992B2 (en) * | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
| EP1645276A1 (de) * | 2004-10-08 | 2006-04-12 | Wageningen Centre for Food Sciences | Behandlung von neurodegenerativen Erkrankungen |
| EP1817023A4 (de) * | 2004-11-16 | 2010-08-18 | Limerick Biopharma Inc | Verfahren und zusammensetzungen zur schmerzbehandlung |
| US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
| US9072729B2 (en) | 2008-01-30 | 2015-07-07 | Agency For Science, Technology And Research | Method for treating fibrosis and cancer with imidazolium and imidazolinium compounds |
| EP2803356A1 (de) * | 2008-03-31 | 2014-11-19 | Agency for Science, Technology and Research | Verfahren zur Behandlung neurologischer Erkrankungen mit Imidazolium und Imidazoliniumverbindungen |
| US8546104B2 (en) * | 2008-08-07 | 2013-10-01 | Lipogen Ltd. | Processes for the preparation of phosphatide salts |
| CA2825428C (en) * | 2010-02-12 | 2022-06-14 | Alexander Vuckovic, M.D., Llc | Compositions and methods for treating depression |
| US9382251B2 (en) * | 2012-07-27 | 2016-07-05 | Chemic Laboratories Inc. | Compositions comprising folic acid derivatives, their preparations and methods of use |
| CA3042699A1 (en) | 2016-11-03 | 2018-08-09 | Alexander Vuckovic, M.D., Llc | Compositions and methods for treating depression |
| US11872241B2 (en) | 2018-11-30 | 2024-01-16 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for reducing major thrombotic events in cancer patients |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0347864A3 (de) * | 1988-06-24 | 1992-04-01 | Andries Johannes Cornelus Strydom | Antiatherosklerose-Mittel |
| IT1229517B (it) * | 1989-01-31 | 1991-09-03 | Bioresearch Spa | Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative. |
| IT1229203B (it) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| DE4117629A1 (de) | 1991-05-29 | 1992-12-03 | Max Planck Gesellschaft | Phospatidylserine |
| PT877563E (pt) * | 1996-01-31 | 2004-08-31 | Univ South Alabama | Preparacoes alimentares e vitaminicas contendo o isomero natural de folatos reduzidos |
| US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
| WO1999037155A1 (en) | 1998-01-27 | 1999-07-29 | Nutramax Laboratories, Inc. | Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances |
-
1999
- 1999-10-13 EP EP99948982A patent/EP1124559B1/de not_active Expired - Lifetime
- 1999-10-13 AT AT99948982T patent/ATE235244T1/de not_active IP Right Cessation
- 1999-10-13 DE DE69906345T patent/DE69906345T2/de not_active Expired - Lifetime
- 1999-10-13 ES ES99948982T patent/ES2194513T3/es not_active Expired - Lifetime
- 1999-10-13 AU AU62022/99A patent/AU6202299A/en not_active Abandoned
- 1999-10-13 JP JP2000579233A patent/JP2002528507A/ja active Pending
- 1999-10-13 WO PCT/EP1999/007688 patent/WO2000025793A1/en active IP Right Grant
- 1999-10-13 CA CA002348390A patent/CA2348390C/en not_active Expired - Fee Related
- 1999-10-13 US US09/830,352 patent/US6514973B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU6202299A (en) | 2000-05-22 |
| CA2348390A1 (en) | 2000-05-11 |
| CA2348390C (en) | 2008-11-25 |
| EP1124559B1 (de) | 2003-03-26 |
| JP2002528507A (ja) | 2002-09-03 |
| DE69906345D1 (de) | 2003-04-30 |
| US6514973B1 (en) | 2003-02-04 |
| ES2194513T3 (es) | 2003-11-16 |
| WO2000025793A1 (en) | 2000-05-11 |
| DE69906345T2 (de) | 2004-02-12 |
| EP1124559A1 (de) | 2001-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE235244T1 (de) | Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten | |
| IL162214A (en) | Pyridine derivatives and pharmaceutical compositions containing the same | |
| TR200001203T2 (tr) | Yeni birleşik maddeler | |
| BR0009830A (pt) | Composições para cuidados com a pele contendo uma combinação de substâncias ativas para cuidados com a pele | |
| DE69931930D1 (de) | Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen | |
| ATE334668T1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
| DE60005560D1 (de) | Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems | |
| LU91145I9 (de) | ||
| IL148079A0 (en) | Human ctla-4 antibodies and compositions containing the same | |
| DE60214179D1 (de) | IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN | |
| ATE232874T1 (de) | Prostaglandin-konjugate zur behandlung von knochenkrankheiten | |
| ES2171723T3 (es) | 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2. | |
| ATE221781T1 (de) | Angiostatische verbindungen und zusammensetzungen zur behandlung des glc1a glaukoms | |
| DE60112330D1 (en) | Pyrazolopyridinderivate | |
| DE50004334D1 (de) | Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane | |
| DE60123238D1 (de) | Zusammensetzungen zur behandlung von autoimmunkrankheiten | |
| DE69907418T2 (de) | Verwendung von makroliden zur behandlung von glaukom | |
| BR9708114A (pt) | Análogos xantona para o tratamento de doenças infecciosas. | |
| DE69835536D1 (de) | Zusammensetzungen zur behandlung von staphylococcus aureus infektionen | |
| MY129668A (en) | Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes | |
| ATE381533T1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
| DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
| ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| ATE266027T1 (de) | Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |